Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.685 USD | +0.94% | -24.29% | +170.03% |
04-18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
03-06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Sales 2024 * | - | Sales 2025 * | 23.49M 1.87B | Capitalization | 107M 8.5B |
---|---|---|---|---|---|
Net income 2024 * | -61M -4.86B | Net income 2025 * | -54M -4.3B | EV / Sales 2024 * | - |
Net cash position 2024 * | 86M 6.85B | Net cash position 2025 * | 68M 5.42B | EV / Sales 2025 * | 1.65 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-2.48
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.61% |
Latest transcript on Rezolute, Inc.
1 day | +0.94% | ||
1 week | -24.29% | ||
Current month | +5.10% | ||
1 month | +10.74% | ||
3 months | +141.44% | ||
6 months | +155.24% | ||
Current year | +170.03% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 25/07/10 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 25/07/10 |
Daron Evans
DFI | Director of Finance/CFO | 50 | 01-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 25/07/10 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 09/02/19 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 19/11/19 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 2.66 | 0.00% | 101 078 |
26/04/24 | 2.66 | +2.31% | 203,470 |
25/04/24 | 2.6 | -10.03% | 455,095 |
24/04/24 | 2.89 | +1.05% | 343,913 |
23/04/24 | 2.86 | -19.21% | 940,007 |
Delayed Quote Nasdaq, April 29, 2024 at 04:51 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+170.03% | 107M | |
-2.70% | 103B | |
+1.66% | 95.28B | |
+1.46% | 22.15B | |
-15.80% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.00% | 16.05B | |
+4.68% | 13.68B | |
+35.49% | 12.17B |
- Stock Market
- Equities
- RZLT Stock